Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy ...
Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results